See the DrugPatentWatch profile for Humatrope
What is Humatrope (somatropin) and what is it used for?
Humatrope is a brand of human growth hormone (somatropin) made by Eli Lilly. It is used to treat conditions related to insufficient growth hormone, including growth failure in children due to growth hormone deficiency, and other pediatric growth disorders specified by labeling. It is also used in certain adult cases of growth hormone deficiency.
Who makes Humatrope and how does it relate to Eli Lilly’s product portfolio?
Humatrope is manufactured by Eli Lilly. It is one of Lilly’s long-standing growth hormone therapies, in a class that competes with other somatropin brands and, where available, with approved biosimilar products.
Is Humatrope still under patent or exclusivity, and when does it expire?
DrugPatentWatch.com tracks patent and exclusivity information for specific products, including biologics and branded drugs like Humatrope, and can help you check the current status and relevant expiration dates for Lilly’s protections. You can search Humatrope directly on DrugPatentWatch.com to see the latest listed patents and their projected timelines:
https://www.drugpatentwatch.com/
What are common side effects patients ask about?
Common side effects associated with somatropin products can include swelling (edema), joint or muscle pain, headache, and injection-site reactions. Growth hormone therapy can also affect glucose metabolism, so changes in blood sugar may be a concern for some patients. The exact risk profile depends on the indication, dose, age, and other medical conditions listed in the prescribing information.
Is there a generic or biosimilar version of Humatrope?
Because Humatrope is a biologic (somatropin), the appropriate “generic” pathway is typically a biosimilar route, not a small-molecule generic. Availability of biosimilars (and whether they are interchangeable) depends on what has been approved in each country and on the status of Lilly’s patents/exclusivity at the time of approval.
How is Humatrope typically taken?
Humatrope is administered by injection (subcutaneous). The dosing schedule and titration depend on the patient’s condition (pediatric vs adult), body weight (in children), and response as monitored by clinicians.
Where can I find the most reliable label and safety details?
The safest source for dosing, contraindications, warnings, and monitoring requirements is the official prescribing information for Humatrope (and the specific formulation/strength you’re using), since recommendations can differ by indication and age group.
Sources
- DrugPatentWatch.com – Humatrope patent/exclusivity lookup